Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Protocol for a randomized controlled trial with a stepped care approach, utilizing PrEP navigation with and without contingency management, for transgender women and sexual minority men with a substance use disorder: Assistance Services Knowledge-PrEP (A.S.K.-PrEP).
Reback CJ, Landovitz RJ, Benkeser D, Jalali A, Shoptaw S, Li MJ, Mata RP, Ryan D, Jeng PJ, Murphy SM. Reback CJ, et al. Among authors: jeng pj. Addict Sci Clin Pract. 2024 Nov 9;19(1):79. doi: 10.1186/s13722-024-00482-6. Addict Sci Clin Pract. 2024. PMID: 39521970 Free PMC article.
Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials.
Murphy SM, Jeng PJ, Poole SA, Jalali A, Vocci FJ, Gordon MS, Woody GE, Polsky D. Murphy SM, et al. Among authors: jeng pj. Addict Sci Clin Pract. 2020 Apr 22;15(1):15. doi: 10.1186/s13722-020-00188-5. Addict Sci Clin Pract. 2020. PMID: 32321570 Free PMC article. Clinical Trial.
Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis.
Murphy SM, Jeng PJ, McCollister KE, Leff JA, Jalali A, Shulman M, Lee JD, Nunes EV, Novo P, Rotrosen J, Schackman BR. Murphy SM, et al. Among authors: jeng pj. Addiction. 2021 Dec;116(12):3444-3453. doi: 10.1111/add.15531. Epub 2021 May 21. Addiction. 2021. PMID: 33950535 Free PMC article. Clinical Trial.
Association between jail-based methadone or buprenorphine treatment for opioid use disorder and overdose mortality after release from New York City jails 2011-17.
Lim S, Cherian T, Katyal M, Goldfeld KS, McDonald R, Wiewel E, Khan M, Krawczyk N, Braunstein S, Murphy SM, Jalali A, Jeng PJ, MacDonald R, Lee JD. Lim S, et al. Among authors: jeng pj. Addiction. 2023 Mar;118(3):459-467. doi: 10.1111/add.16071. Epub 2022 Nov 16. Addiction. 2023. PMID: 36305669 Free PMC article.
Jail-based medication for opioid use disorder and patterns of reincarceration and acute care use after release: A sequence analysis.
Lim S, Cherian T, Katyal M, Goldfeld KS, McDonald R, Wiewel E, Khan M, Krawczyk N, Braunstein S, Murphy SM, Jalali A, Jeng PJ, Rosner Z, MacDonald R, Lee JD. Lim S, et al. Among authors: jeng pj. J Subst Use Addict Treat. 2024 Mar;158:209254. doi: 10.1016/j.josat.2023.209254. Epub 2023 Dec 10. J Subst Use Addict Treat. 2024. PMID: 38072387
32 results